Koichi Asanuma

Koichi Asanuma

Auto-generated profile, based on publicly available information

Koichi Asanuma

Division of Laboratory Medicine, Sapporo Medical University Hospital, Sapporo, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RKRyo Kobayashi
Ryo Kobayashi
RMRyosei Murai
Ryosei Murai
KAKoichi Asanuma
Koichi Asanuma
YFYoshihiro Fujiya
Yoshihiro Fujiya
STSatoshi Takahashi
Satoshi Takahashi

1 October 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RKRyo Kobayashi
Ryo Kobayashi
RMRyosei Murai
Ryosei Murai
MMMikako Moriai
Mikako Moriai
SNShinya Nirasawa
Shinya Nirasawa
HYHitoshi Yonezawa
Hitoshi Yonezawa
STSatoshi Takahashi
Satoshi Takahashi

6 September 2021 in Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YSYuki Sato
Yuki Sato
TKTakashi Kondo
Takashi Kondo
MMMikako Moriai
Mikako Moriai
SNShinya Nirasawa
Shinya Nirasawa
MSMasachika Saeki
Masachika Saeki
STSatoshi Takahashi
Satoshi Takahashi
Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is rapidly spreading globally. Early diagnosis plays an essential role in controlling the infection. Therefore, early and accurate SARS-CoV-2 detection assays along with easy operation are required. The aim of this study was to compare the clinical performance of the Ampdirect™ 2019-nCoV Detection Kit (SHIMADZU assay), which does not require RNA purification steps, with that of the preexisting SARS-CoV-2 detection assays, which use a purified RNA template. Methods A total of 71 samples (65 nasopharyngeal specimens and 6 sputum specimens) were collected from 32 individuals, including patients infected with SARS-CoV-2 and those with suspected infection. The sensitivity and kappa ( κ ) coefficient were assessed between the SARS-CoV-2 detection assays using the reference standard, which was defined as a true positive result by any one of the four SARS-CoV-2 detection assays. Results The overall sensitivity and κ coefficient of the SHIMADZU assay were 86.0% (95% confidence interval [CI]: 77.9–94.2) and 0.83 (95% CI: 0.69–0.96), respectively. In particular, among the 18 samples collected within 10 days from symptom onset, the sensitivity and κ coefficient of the SHIMADZU assay were 100% and 1.0, respectively. Conclusions Although a relatively small number of samples was evaluated, the SHIMADZU assay showed good analytical performance and as such would be highly useful for the detection of SARS-CoV-2. The test can be performed easily and quickly and has the potential for future applications in situations where a highly sensitive diagnosis is required.

8 August 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YFYoshihiro Fujiya
Yoshihiro Fujiya
YSYuki Sato
Yuki Sato
YKYuki Katayama
Yuki Katayama
SNShinya Nirasawa
Shinya Nirasawa
MMMikako Moriai
Mikako Moriai
STSatoshi Takahashi
Satoshi Takahashi

16 August 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RKRyo Kobayashi
Ryo Kobayashi
RMRyosei Murai
Ryosei Murai
YSYuki Sato
Yuki Sato
MNMami Nakae
Mami Nakae
SNShinya Nirasawa
Shinya Nirasawa
STSatoshi Takahashi
Satoshi Takahashi

1 October 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
HYHitoshi Yonezawa
Hitoshi Yonezawa
STShingo Tanaka
Shingo Tanaka
MFMomoko Furuya
Momoko Furuya
KYKoji Yamada
Koji Yamada
KAKoichi Asanuma
Koichi Asanuma
JKJunji Kato
Junji Kato